The purpose of this study is to provide real world data on treatment with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients. The primary purpose is to evaluate overall survival (OS) in mCRPC patients treated with enzalutamide who have previously undergone treatment with chemotherapy (docetaxel) (post chemo patients). This study will also evaluate treatment duration with enzalutamide in patients pre- and post-chemo.
The data source in this study is a local hospital registry created from a patient follow up of prostate cancer patients.
Study Type
OBSERVATIONAL
Enrollment
211
oral
intravenous infusion
Site SE46001
Malmö, Sweden
Overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated with enzalutamide, who have previously undergone treatment with chemotherapy (docetaxel)
Overall survival is defined as time from initiation to death of any cause.
Time frame: Up to a maximum of four years
Treatment duration of enzalutamide in pre chemo mCRPC patients
Treatment duration is defined as time from initiation to treatment discontinuation of any cause.
Time frame: Up to a maximum of four years
Treatment duration of enzalutamide in post chemo mCRPC patients
Treatment duration is defined as time from initiation to treatment discontinuation of any cause.
Time frame: Up to a maximum of four years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.